Anti-R7V antibodies as therapeutics for HIV-infected patients in failure of HAART.
Many attempts to use therapeutic antibodies to treat HIV have been unsuccessful owing to the high variability of the viral proteins, the multiplicity of the cellular targets, and the conformational changes of the gp120 glycoprotein during cell binding. A new concept of identifying a cellular antigen associated with the HIV envelope was investigated. The characterized epitope, R7V, is responsible for the formation of antibodies protective against HIV in non-progressor patients. The purified anti-R7V antibodies neutralize all HIV isolates, including the escape mutants after highly active antiretroviral therapy, creating a new therapeutic tool for the treatment of HIV-infected patients.
Haslin
Camille
C
URRMA R&D, Centre de Vie Agora, ZI des Paluds, BP 1055, 13781 Cedex, Aubagne, France. cherma@urrma.fr
Chermann
Jean Claude
JC
D023241:Antiretroviral Therapy, Highly Active; D024921:Drug Resistance, Multiple, Viral; D000939:Epitopes; D015483:HIV Antibodies / Q000276:immunology / Q000302:isolation & purification* / Q000627:therapeutic use*; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods; D017211:Treatment Failure
D000939:Epitopes; D015483:HIV Antibodies